Cognition Therapeutics announced that its President and Chief Executive Officer, Lisa Ricciardi, presented at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026. The presentation included an update on the company’s development programs in Alzheimer’s disease and dementia with Lewy bodies (DLB).

Conference Presentation and Webcast

During the virtual conference, Ms. Ricciardi provided an overview of Cognition Therapeutics’ clinical pipeline and highlighted recent progress across its neurodegenerative disease programs. The presentation was made available via a live webcast through the company’s investor relations website, with an archived replay scheduled to remain accessible for 90 days.

Pipeline Update: Zervimesine (CT1812)

A key focus of the update was the company’s lead investigational candidate, zervimesine (formerly CT1812), which is being evaluated across multiple neurodegenerative disease indications.

Zervimesine was being studied in the Phase 2 START trial in patients with mild cognitive impairment (MCI) and early Alzheimer’s disease. The company also reviewed prior Phase 2 clinical programs that had been completed in dementia with Lewy bodies, mild-to-moderate Alzheimer’s disease, and geographic atrophy secondary to dry age-related macular degeneration.

Clinical Progress and Development Plans

The company reported that zervimesine had demonstrated encouraging efficacy signals in the Phase 2 SHIMMER study in patients with dementia with Lewy bodies. Based on these findings, Cognition Therapeutics stated that it planned to advance the program into a late-stage clinical trial targeting DLB psychosis.

Across completed and ongoing studies, zervimesine had generally been well tolerated, according to the company.

Regulatory Update

Cognition Therapeutics also noted that the United States Adopted Names (USAN) Council had officially designated “zervimesine” as the nonproprietary name for CT1812.

Post-Conference Outlook

The presentation provided investors with updated insight into the company’s clinical strategy as it continued to advance therapies targeting neurodegenerative diseases with high unmet medical need.